Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
August 12, 2019 7:14 AM EDT
Akero Therapeutics (NASDAQ: AKRO) reported Q2 EPS of ($2.21), $1.85 worse than the analyst estimate of ($0.36).
Second Quarter 2019 Financial Results
Research and development expenses for the three-month and six-month periods ended June 30, 2019 were $6.0 million and $10.0 million, respectively, compared to $8.4 million and $8.6 million for the comparable periods in 2018. Research and development expenses in 2019 are attributable to direct costs related to our AKR-001 program, including third-party contract manufacturing, CRO costs associated with the BALANCED trial and internal personnel costs. Research and development expenses in 2018 were primarily attributable to $8.0 million of one-time cash and non-cash product licensing...
More
